Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran in Children With Heterozygous Familial Hypercholesterolemia (ORION-20)
NCT06597019Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Dec 2024
- Primary completion
- Mar 2028
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 23
01
Overview
A Phase 3 trial of inclisiran in familial hypercholesterolemia (FH), sponsored by Novartis. Started Dec 2024; status: recruiting.
02
Drugs
inclisiran
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NCT06597019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06597019.